Abstract: A method of characterizing cellular phenotypes includes receiving multi-parameter cellular and sub-cellular imaging data for a number of tissue samples from a number of patients or a number of multicellular in vitro models, performing cellular segmentation on the multi-parameter cellular and sub-cellular imaging data to create segmented multi-parameter cellular and sub-cellular imaging data, and performing recursive decomposition on the segmented multi-parameter cellular and subcellular imaging data to identify a plurality of computational phenotypes. The recursive decomposition includes a plurality of levels of decomposition with each level of decomposition including soft/probabilistic clustering and spatial regularization, and each cell in the segmented multi-parameter cellular and subcellular imaging data is probabilistically assigned to one or more of the plurality of computational phenotypes.

Abstract: Methods are disclosed for treating an autoimmune disorder in a subject in need thereof. These methods include administering to the subject a pharmaceutical preparation comprising isolated matrix bound vesicles (MBV) derived from extracellular matrix. The administration can be systemic. In some embodiments, the subject has rheumatoid arthritis or psoriasis.

Abstract: Small molecule inhibitors that block the interaction between B-cell lymphoma 10 protein (BCL10) and mucosa- associated lymphoid tissue lymphoma translocation protein 1 (MALT1), thereby inhibiting both the protease and scaffolding activities of MALT1, and MALT1- dependent downstream signaling, including IL-6 and IL-10 secretion by B-cell lymphoma cells and IL-2 transcription and secretion by Jurkat T cells.

Abstract: Disclosed herein are chimeric antigen receptors (CARs) that include (a) an extracellular scFv comprising a light chain variable domain (VL) a heavy chain variable domain (VH), wherein the scFv specifically binds to an antigen of interest; (b) a CD8 hinge domain and transmembrane domain; and (c) a cytoplasmic domain comprising (i) a TIM-3 cytoplasmic domain and an intracellular signaling domain, wherein (a)-(c) are in N-terminal to C-terminal order. Also disclosed are nucleic acid molecules encoding these CARs, host cells transformed with these nucleic acids, and the use of these compositions for treating a subject, such as a subject with a tumor.

Abstract: The present disclosure relates to compounds, compositions, and methods for the inducing neurodegenerative disease pathologies. In one aspect, disclosed herein is a nucleotide sequence encoding a chimeric polypeptide, comprising: a first nucleotide sequence encoding a light-induced oligomerization domain and a second nucleotide sequence encoding a neurodegenerative disease in target protein. Disclosed herein is a method of inducing a neurodegenerative disease pathology in a cell, comprising the steps: introducing into the cell an expression vector encoding a chimeric polypeptide, comprising: a first nucleotide sequence encoding a light-induced oligomerization domain and a second nucleotide sequence encoding a low complexity domain from a neurodegenerative disease target protein, wherein the first nucleotide sequence is operably linked to a promoter; expressing the chimeric polypeptide; and inducing oligomerization of the chimeric polypeptide by stimulation with blue light.

Abstract: A load cell apparatus includes a base member, a cap member, a number of first members provided between the base member and the cap member and forming at least a portion of a support wall of the load cell apparatus, and a plurality of strain gauges directly coupled to the number of first members, the plurality of strain gauges being positioned to measure an axial load applied to the load cell in a direction extending from the cap member to the base member.

Abstract: EphA2 T-cell epitope are provided herein. The epitopes include peptides corresponding to specific fragments of human EphA2 protein containing one or more T-cell epitopes, and conservative derivatives thereof. The EphA2 T-cell epitopes are useful in an assay, such as an ELISPOT assay, that may be used to determine and/or quantify a patient's immune responsiveness to EphA2. The epitopes also are useful in methods of modulating a patient's immune reactivity to EphA2, which has substantial utility as a treatment for cancers that overexpress EphA2, such as renal cell carcinoma (RCC). The EphA2 epitopes also can be used to vaccinate a patient against EphA2, by in vivo or ex vivo methods.

Abstract: A linear variable differential pitot tube includes a primary solenoid, a first secondary solenoid, a second secondary solenoid, wherein the primary solenoid is positioned in between the first secondary solenoid and the second secondary solenoid, wherein the first secondary solenoid and the first secondary solenoid have identical geometries, and a high permeability magnetic core, the high permeability magnetic core being structured to move relative to the primary solenoid, the first secondary solenoid, and the second secondary solenoid. Also, a system and method for measuring the localized velocity of a flow of a fluid using the linear variable differential pitot tube.

Abstract: A system for assisting a user with navigating a set of stairs includes a pulley system positioned adjacent to the stairs, the pulley system including a first pulley, a second pulley, and an elongated member coupled to and looped around the first pulley and the second pulley. The system further includes a motor coupled to the first pulley, a sensing assembly operatively coupled to the pulley system, the sensing assembly being structured and configured to sense that a force is being applied to or that is about to be applied to the elongated member by the user, and a controller coupled to the motor and the sensing assembly. The controller is structured and configured to, responsive to the sensing assembly sensing the force, turn the motor on to drive the first pulley.

Abstract: A neurofeedback system includes an EEG apparatus, a presentation apparatus and a controller. The controller is configured to: (i) cause the presentation apparatus to display an overlaid image to the user that comprises a first image flickering at a first frequency and a second image flickering at a second frequency different than the first frequency, the first image being an affective distractor stimulus image and the second image being a task-relevant stimulus image, (ii) receive from the EEG apparatus a number of first steady-state visual evoked potential (SSVEP) signals generated in response the first image of the overlaid image and a number of second SSVEP signals generated in response the second image of the overlaid image, and (iii) calculate feedback indicative of how much attention of the was user allocated to the task-relevant stimulus image versus how much attention of the user was allocated to the affective distractor stimulus image.

Abstract: Disclosed herein are various bioreactor devices and systems for growing cellular material, and related methods of growing cellular material. In some cases, a system can include a well plate having a plurality of wells and a bioreactor situated in each well of the well plate. In some cases, a bioreactor can include an inner body which divides the bioreactor into several distinct chambers and facilitates the growth of a multi-tissue sample in the bioreactor. In some cases, a system can include a mechanical actuator situated to mechanically stress tissues grown in a bioreactor.

Abstract: The present disclosure relates to the engraftment and proliferation of cells in fat-associated lymphoid clusters (“FALCs” or “milky spots”), which may be used to generate functional ectopic tissue. The present disclosure further provides methods and compositions for grafting and proliferating cells, in FALCs by activating the lymphotoxin beta receptor (LT?R) and/or NF-?B-inducing kinase (NIK) signaling pathway. The present disclosure also provides for methods and compositions to establish ectopic liver tissue in FALCs (milky spots) and to use such ectopic liver tissue for therapeutic benefit, and provides methods and compositions to generate ectopic kidney tissue in FALCs, which can be used in a subject for therapeutic benefit.

Abstract: Described herein is a new antidote for the rapid elimination of carbon monoxide from hemoglobin, including brain, heart, and red cell hemoglobin. The disclosed therapy involves the use of modified human globins, particularly neuroglobins modified at residue 64 and cytoglobins modified at residue 81, which bind carbon monoxide with extremely high affinity. The monomeric mutant globins are infused into blood, where they rapidly and irreversibly sequester carbon monoxide, and thus limit toxic effects of carbon monoxide on cellular respiration and oxygen transport and utilization.

Abstract: The invention includes a cationic cyclopentadienyliron dicarbonyl complex according to the general structure (I): wherein, Y is (CH2)n or (CH2)mA(CH2)n, A is O, NSO2R, S, or CR1R2, each of R, R1 and R2 with respect to A is independently alkyl or aryl, n is an integer from 1 to 8, m+n is an integer from 2 to 7, Z is alkyl, aryl, heteroaryl, or CF3, and X is BF4?, ClO4?, PF6?, AsF6?, or SbF6?.

Abstract: Provided are ex vivo and in vivo methods utilizing therapeutic genes for treatment of male and female infertility, including non-obstructive azoospermia (NOA) and premature ovarian insufficiency (POI) and comorbid diseases, with or without transmitting the therapeutic gene to offspring of the infertile subject. Germline gene therapy methods are also described to reduce or eliminate disease from families with or without transmission of the therapeutic gene to offspring.

Abstract: h A method for using a trained machine learning model to predict risk of incident opioid use disorder (OUD) and/or of N an opioid overdose episode for a subject. The method comprises using at least one computer hardware processor to perform: accessing data associated with the subject, wherein the data comprises values for a plurality of predictors; generating input features for the trained machine learning model from the data; and providing the input features as input to the trained machine learning model to obtain an output indicative of the risk of OUD and/or of the opioid overdose episode for the subject, wherein the trained machine learning model comprises a first plurality of values for a respective first plurality of parameters, the first plurality of values used by the at least one computer hardware processor to obtain the output from the input features.

Abstract: A method of predicting cancer recurrence risk for an individual includes receiving patient spatial multi-parameter cellular and sub-cellular imaging data for a tumor of the individual, and analyzing the patient spatial multi-parameter cellular and sub-cellular imaging data using a prognostic model for predicting cancer recurrence risk to determine a predicted cancer recurrence risk for the individual, wherein the joint prognostic model is based on spatial correlation statistics among features derived for a plurality of intra-tumor spatial domains from spatial multi-parameter cellular and sub-cellular imaging data obtained from a plurality of cancer patients.

Abstract: The invention relates to biomimetic, biodegradable composites including a magnesium (Mg) alloy mesh and a polymer/extracellular matrix (ECM). These hybrid composites, more particularly, are useful for the fabrication of medical implant devices, e.g., scaffolds, and are effective for bone regeneration. The fabrication process includes creating the Mg alloy mesh, and concurrently electrospinning the polymer and electrospraying the ECM onto the mesh.

Abstract: A system for providing a boosted decision tree (BDT) for use on an electronic device to provide an event score based on a user input event, where the device includes: a machine learning trainer configured to create a trained BDT from an untrained BDT by determining parameters for the untrained BDT; a nanosecond optimizer configured to create an optimized BDT, the nanosecond optimizer including at least one of a tree flattener, a tree merger, a score normalizer, a tree remover, and a cut eraser; and a converter coupled to the nanosecond optimizer and configured to receive the optimized BDT from the nanosecond optimizer and convert the optimized BDT to a language for high-level-synthesis to produce a hardware description language representation of the optimized BDT, wherein the hardware description language representation of the optimized BDT is structured and configured to be implemented in firmware provided on the electronic device.

Abstract: Triosephosphate isomerase deficiency (TPI Df) is a devastating childhood degenerative disease for which there are currently no treatments. Pathogenesis of this disease is driven by mutations that destabilize the TPI protein. A genome-wide RNAi screen in Drosophila to identify regulators of TPI stability is described. The screen identified 25 proteins that are critical to TPI stability, each of which has a human ortholog. Methods of promoting TPI protein stability and treating TPI Df in a subject by administering a therapeutically effective amount of an agent that inhibits expression or activity of one of the identified regulators are described. Also described is a method for the identification of agents capable of promoting stability of mutant TPI. Methods for treating a subject who has TPI Df by administering an agent that promotes stability of mutant TPI is also described.